Keymed Biosciences' Gastric Cancer Drug Meets Phase 3 Goal; Shares Fall 5%

MT Newswires Live07-28

Keymed Biosciences (HKG:2162) and AstraZeneca's global phase 3 trial of CMG901 met its primary endpoint in patients with CLDN18.2-positive advanced gastric cancer, according to a Tuesday filing with the Hong Kong bourse.

The trial showed the antibody-drug conjugate significantly improved overall survival compared with investigator's choice of treatment in patients receiving second- or later-line therapy.

CMG901 demonstrated a safety profile consistent with previous studies, with no new safety signals identified, the company said.

Following the positive Phase 3 results, the company estimates peak annual sales of $3 billion to $5 billion for the drug candidate.

Shares of the biopharmaceutical company were down over 5% in recent trade.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2654076063?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-28 14:43","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2654076063","market":"sg","top_or_hot":-1,"title":"Keymed Biosciences' Gastric Cancer Drug Meets Phase 3 Goal; Shares Fall 5%","media":"MT Newswires Live","content":"<html><body><p> Keymed Biosciences (HKG:2162) and AstraZeneca's global phase 3 trial of CMG901 met its primary endpoint in patients with CLDN18.2-positive advanced gastric cancer, according to a Tuesday filing with the Hong Kong bourse.</p><p>The trial showed the antibody-drug conjugate significantly improved overall survival compared with investigator's choice of treatment in patients receiving second- or later-line therapy.</p><p>CMG901 demonstrated a safety profile consistent with previous studies, with no new safety signals identified, the company said.</p><p>Following the positive Phase 3 results, the company estimates peak annual sales of $3 billion to $5 billion for the drug candidate.</p><p>Shares of the biopharmaceutical company were down over 5% in recent trade.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Keymed Biosciences' Gastric Cancer Drug Meets Phase 3 Goal; Shares Fall 5%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nKeymed Biosciences' Gastric Cancer Drug Meets Phase 3 Goal; Shares Fall 5%\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-07-28 14:43</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Keymed Biosciences (HKG:2162) and AstraZeneca's global phase 3 trial of CMG901 met its primary endpoint in patients with CLDN18.2-positive advanced gastric cancer, according to a Tuesday filing with the Hong Kong bourse.</p><p>The trial showed the antibody-drug conjugate significantly improved overall survival compared with investigator's choice of treatment in patients receiving second- or later-line therapy.</p><p>CMG901 demonstrated a safety profile consistent with previous studies, with no new safety signals identified, the company said.</p><p>Following the positive Phase 3 results, the company estimates peak annual sales of $3 billion to $5 billion for the drug candidate.</p><p>Shares of the biopharmaceutical company were down over 5% in recent trade.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1583","symbol_name":"高瓴概念","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2654076063","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2654076063","pubTimestamp":1785221026,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Keymed Biosciences  and AstraZeneca's global phase 3 trial of CMG901 met its primary endpoint in patients with CLDN18.2-positive advanced gastric cancer, according to a Tuesday filing with the Hong Kong bourse.The trial showed the antibody-drug conjugate significantly improved overall survival compared with investigator's choice of treatment in patients receiving second- or later-line therapy.CMG901 demonstrated a safety profile consistent with previous studies, with no new safety signals identified, the company said.Following the positive Phase 3 results, the company estimates peak annual sales of $3 billion to $5 billion for the drug candidate.Shares of the biopharmaceutical company were down over 5% in recent trade.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1583":"高瓴概念","BK1587":"次新股","02162":"康诺亚-B","BK1161":"生物科技","BK1574":"生物医药B类股"},"translate_title":"Keymed Biosciences 胃癌药物达到 3 期目标；股价下跌 5%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02162":1},"content_text":"Keymed Biosciences (HKG:2162) and AstraZeneca's global phase 3 trial of CMG901 met its primary endpoint in patients with CLDN18.2-positive advanced gastric cancer, according to a Tuesday filing with the Hong Kong bourse.The trial showed the antibody-drug conjugate significantly improved overall survival compared with investigator's choice of treatment in patients receiving second- or later-line therapy.CMG901 demonstrated a safety profile consistent with previous studies, with no new safety signals identified, the company said.Following the positive Phase 3 results, the company estimates peak annual sales of $3 billion to $5 billion for the drug candidate.Shares of the biopharmaceutical company were down over 5% in recent trade.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2654076063","isCrawlerRequest":true}